Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $26.0500 (-0.15%) ($25.9200 - $26.8800) on Tue. Mar. 20, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.52% (three month average) | RSI | 61 | Latest Price | $26.0500(-0.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) IWM(18%) IWO(18%) QQQ(18%) | Factors Impacting ADMS price | ADMS will decline at least -2.26% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-9%) UUP(-7%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.26% (StdDev 4.52%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
Resistance Level | $26.21 | 5 Day Moving Average | $26.49(-1.66%) | 10 Day Moving Average | $26.7(-2.43%) | 20 Day Moving Average | $26.21(-0.61%) | To recent high | -38.9% | To recent low | 6.9% | Market Cap | $737m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |